Oral administration of sucroferric oxyhydroxide during hemodialysis sessions against resistant hyperphosphatemia
Not Applicable
Recruiting
- Conditions
- Resistant hyperphosphatemia in maintenance hemodialysis patients
- Registration Number
- JPRN-UMIN000031337
- Lead Sponsor
- Dialysis Center, JA Toride Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
patients with risk od aspiration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method reduction of serum phosphate levels
- Secondary Outcome Measures
Name Time Method Serum FGF-23 levels, adverse events